SEC Form 4 · accession 0001213900-26-076431
KAZIA THERAPEUTICS LTD · KZIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven R. S. Coffey
Director
Period of report
Jan 8, 2026
Accepted (ET)
Jul 8, 2026 · 4:59 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001075880
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $9.10 | Jan 8, 2026 | A | 100,000 | A | — | — | ADSs | 100,000 | 100,000 | D |
Explanation of responses
- F1Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.